Effectiveness of Liquid Crystal Contact Thermography in Detecting Pathological Changes in Female Breasts

Breast Cancer Clinical Trial

Official title:

Investigation of the Effectiveness of Liquid Crystal Contact Thermography in Detecting Pathological Changes in Female Breasts Compared to Standard Diagnostic Methods of Breast Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03735550
• Other study ID #: INNOMED_BRASTER_2016_01
• Status: Active, not recruiting
• Start date: February 1, 2017
• Est. completion date: January 31, 2019

Study information

• Verified date: December 2018
• Source: Jagiellonian University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The study is designed to evaluate the effectiveness of liquid crystal contact thermography in detecting pathological changes in female breasts compared to standard diagnostic methods.

Description:

The study is a multicentre, observational, cross-sectional, open and monitored trial involving approx. 3000 females who will be subject to an examination using liquid crystal contact thermography device as a complementary tool to standard diagnostic imaging procedures of the breast glands. The study is conducted in specialist outpatient clinics. Patients are eligible to participate in the study upon signing the informed consent form. There is no follow up after the thermographic examination.

The study will comprise of a single registration of thermographic images of the breasts which will be subjected to automatic and expert analysis by radiologists.

Primary objective of the study is to determine and compare the diagnostic efficacy of breast thermography using a medical device based on liquid crystal contact thermography to standard of care.

The subjects were divided into three groups based on age and Breast Imaging Reporting and Data System (BI-RADS). Thermography was performed as a complementary modality to standard of care. In group A, the investigators recruited women aged 18-49, who has a breast ultrasound performed and a result of BI-RADS 4b, 4c or 5. In group B, the investigators recruited women over 50 years of age with either a result of BI-RADS 4, 4a, 4b, 4c or 5 on mammography or BI-RADS 4a, 4b, 4c or 5 on ultrasound. If a positive result was present on one of these examinations, the other examination needed to be performed. Lastly, in group C, the investigators recruited women aged 18 and above with a BI-RADS score of 1 or 2 on mammography and/or breast ultrasound.

Predicted duration of the study is approximately 24 months.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 3000
• Est. completion date: January 31, 2019
• Est. primary completion date: January 30, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• a woman aged 18 or above (without any upper age limit) who gives informed consent to the participation in the study by signing the Informed Consent Form and meets one of the below requirements may take part in the study:

1. For women aged 18-49: ultrasound imaging of breasts was performed; category of the final assessment of the study according to the BI-RADS scale 4b, 4c or 5.

2. For women aged 50 or above (in the B group, a mammography examination in the final assessment category according to the BI-RADS scale 4, 4a, 4b, 4c or 5; or the breast ultrasound in the final assessment category according to the BI-RADS scale 4a, 4b, 4c or 5 (but both examinations are obligatory); in the C2 group, mammography or breast ultrasound in the final category of the examination assessment according to the BI-RADS scale 1, 2 (but both examinations are obligatory). -

Exclusion Criteria:

1. Performed invasive diagnostics of changes in breasts (treatment performed less than 12 months before inclusion into the study) - relates to a core- needle and mammotome biopsy (also a fine-needle biopsy performed up to 4 weeks before inclusion to the study).

2. A breast surgery within 12 months before inclusion into the study (including cosmetic surgeries, i.e. aesthetic implants, fat-graft transfer and hyaluronic acid injection into breasts.

3. A visible, considerable breasts asymmetry that makes the examination with an equal number of matrix applications on both breasts impossible.

4. A visible considerable breast deformation including appearance of scarring on the breast skin which makes adjustment of the entire matrix surface to the breast gland impossible.

5. Previous or ongoing anti-tumour treatment due to the breast cancer.

6. Symptomatic acute or chronic breast inflammation, with visible features of inflammation: pain, increased temperature, skin redness, swelling, breast abscesses, breast vessels thrombosis.

7. Injury to the breasts with visible clinical properties of extravasation.

8. A patient is suffering from an active infection with the body temperature equal to or more than 37.5°C.

9. Pregnancy and lactation (pregnancy must be ruled out based on the last period date (< 30 days), or using effective contraception - with regard to women from group A, in case of any doubts performance of the stripe pregnancy test).

10. Alcohol consumption on the day of the visit at the doctor's.

11. Intensive physical effort up to 30 minutes before thermographic examination.

12. Bath/shower (approximately 2 hours before thermographic examination).

13. Using sauna/ steam bath on the day of examination, before thermographic examination.

14. Cosmetic and beauty treatments before examination: peeling within the neckline and breasts, hair removal within armpits, application of cosmetics on the breast skin (approximately 2 hours before thermographic examination).

15. A direct stay close to the heat or cold sources such as heaters or air conditioners 30 minutes before thermographic examination.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Device:
• Contact thermographic breast examination device
A class 2a medical device being an active non-invasive multiple-use thermographic contact tester that uses a technology of passive liquid crystal matrices placed in the head of the device that records a thermographic image of breast glands with application of these matrices to the examined organ. The examination is non-invasive.

Locations

Country	Name	City	State
Poland	BIALOSTOCKIE CENTRUM ONKOLOGII im. Marii Sklodowskiej - Curie	Bialystok
Poland	"Zaklad Radiologii i Diagnostyki Obrazowej, Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny"	Brzozów
Poland	CM MEDYK	Czestochowa
Poland	Klinika Artvein	Gdansk
Poland	LUX MED.	Gdansk
Poland	NZOZ INTERMED Sp. z o.o.	Gryfino
Poland	Centrum Medyczne Femina	Katowice
Poland	NZOZ Promont MED.	Kielce
Poland	KOMED	Konin
Poland	"Centrum Medyczne Zdrowie Kobiety"	Kraków
Poland	Gabinety Babie Lato	Kraków
Poland	Niepubliczy Zaklad Opieki Zdrowotnej Polikmed	Kraków
Poland	SP ZOZ Szpital Uniwersytecki w Krakowie	Kraków
Poland	Zaklad Radiologii i Diagnostyki Obrazowej Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie Oddzial w Krakowie	Kraków
Poland	Centrum Medyczne Salve Medica	Lódz
Poland	WWCOT w Lodzi	Lódz
Poland	Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli	Lublin
Poland	ONKO-TEAM Diagnostyka	Poznan
Poland	Specjalistyczna Przychodnia Lekarska WILMED	Warsaw
Poland	"Centrum Profilaktyki Nowotworów Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie "	Warszawa
Poland	Centrum Medyczne Mila	Warszawa
Poland	NZOZ i POZ Centrum Medyczne Saska Kepa	Warszawa
Poland	Mazowiecki Szpital Onkologiczny	Wieliszew
Poland	Zaklad Diagnostyki Chorób Piersi Dolnoslaskie Centrum Onkologii we Wroclawiu	Wroclaw

Sponsors (4)

Lead Sponsor	Collaborator
Jagiellonian University	Bioscience, S.A., Braster S.A., National Center for Research and Development, Poland

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Diagnostic efficacy of liquid crystal contact thermography using a manual assessment algorithm as compared with ultrasound and/or mammography and breast biopsy.	The outcome is measured as number of subjects with pathological diagnosis of cancer. Subjects will be analysed based on age, 18-49 and women over 50.	2 years
Secondary	Validation of new algorithms for automatic interpretation of thermographic images of the breast gland assessed by sensitivity, specificity, positive and negative predicate values with 95% confidence intervals using Jeffrey's method.	Comparison of the field below the Receiver Operating Characteristic (ROC) curve (C statistic) and sensitivity and specificity between the age and recruitment groups as well as between the manual algorithm and automatic interpretation algorithm will take place with the use of Wald and McNemar tests.; Values P < 0.05 will be recognised as statistically significant.	6 months
Secondary	Safety of liquid crystal contact thermography device assessed by absolute and relative number of adverse events relating to the investigated medical device and patient groups. The data is collected in electronic Case Report Form (eCRF).		2 years